NEWS & MEDIA

Media Coverage

Explore the stories, insights, and perspectives from the media as we continue our mission to provide effective and scientifically-proven treatments for gastrointestinal health in humans and animals.

Small Caps

Interview: Anatara Lifesciences’ irritable bowel syndrome trial shows promising progress

Small Caps

Anatara Lifesciences on track with recruitment for Stage 2 of GaRP IBS trial

Yahoo Finance

Shining a Spotlight on IBS: Anatara Lifesciences Makes Strides in Phase II Trial during IBS Awareness Month

Valiant CEO

IBS in Australia: A Call for Action and Anatara Lifesciences’ Innovative Solution

Digital Journal

Exploring the Profound Impact of IBS in Australia and Anatara Lifesciences’ GaRP-IBS Trial

Auspreneur

Examining The Impact Of Ibs In Australia And Anatara Lifesciences’ Garp-Ibs Trial

Tech Bullion

Anatara Lifesciences’ GaRP-IBS Trial and the Battle Against IBS in Australia

The Australian Business Journal

Understanding the Impact of IBS in Australia: The Implications of Anatara Lifesciences’ GaRP-IBS Trial

Small Caps

Anatara Lifesciences embarks on Stage 2 of GaRP trial for treatment of irritable bowel syndrome

Small Caps

Anatara Lifesciences’ Stage 2 GaRP trial for IBS treatment gains momentum

Small Caps

Podcast: Anatara Lifesciences reaches milestone in progression of Phase II IBS trial

Small Caps

IBS Awareness Month: Anatara Lifesciences trial offers hope for millions

Small Caps

Anatara Lifesciences opens GaRP therapy trial extension to treat irritable bowel syndrome

The Australian Business Journal

Interview with Dr. David Brookes, Executive Chair of Anatara Lifesciences

Business Insider

Anatara Lifesciences Announce Revolutionary Breakthroughs in GaRP IBS Treatment
Top Stories
Multimedia Gallery
Anatara e-news
Industry Links
Media Contacts
Evidence-based treatments for gastrointestinal health
About Us
Products
Investments
News & Media
Contact Us
Want to stay up to date with our trials and latest news?
Sign up here

    All rights reserved © Anatara Lifesciences 2024